Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CinCor Pharma, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
03/06/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
03/03/2023 SC 13D/A Sofinnova Capital IX reports a 0% stake in CinCor Pharma, Inc.
03/01/2023 SC 13D/A Sofinnova Venture Partners X, L.P. reports a 0% stake in CinCor Pharma, Inc.
02/28/2023 SC 13D/A 5AM Ventures VI, L.P. reports a 0% stake in CinCor Pharma, Inc.
02/28/2023 SC 13D/A GENERAL ATLANTIC, L.P. reports a 0% stake in CinCor Pharma, Inc.
02/24/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/24/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Fourth Amended and Restated Certificate of Incorporation of CinCor Pharma, Inc. (filed herewith)",
"Second Amended and Restated Bylaws of CinCor Pharma, Inc. (filed herewith)"
02/24/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
02/24/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/24/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/23/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/23/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/14/2023 SC 13G PERCEPTIVE ADVISORS LLC reports a 5.9% stake in Cincor Pharma Inc.
02/13/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/13/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/03/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
01/23/2023 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
01/23/2023 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
01/18/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
01/11/2023 SC 13D/A GENERAL ATLANTIC, L.P. reports a 9.6% stake in CinCor Pharma, Inc.
01/09/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
01/09/2023 8-K Quarterly results
01/09/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
11/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension Primary endpoint in Intention to Treat was not met despite large absolute reductions in Systolic Blood Pressure 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population Safety profile and tolerability consistent with BrigHtn Phase 2 data; no patient discontinued due to treatment-related adverse events; low hyperkalemia incidence HALO in combination with BrigHtn informs the dose and study populations anticipated to be recruited into Phase 3 trials pending confirmation by FDA at planned end of Phase 2 meeting in January 2023; Phase 3 t..."
11/08/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg -- CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart Association Scientific Sessions. Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase. “We were honored to present our Phase 2 BrigHtn data as part of a late-breaki...",
"CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension Clinically significant and dose-dependent reduction in blood pressure with baxdrostat Highly selective mechanism of action with no meaningful impact on cortisol supports first-in-class potential Potential treatment for the 10-12 million patients in the US alone with treatment-resistant hypertension WALTHAM, MA, November 7, 2022 -- CinCor Pharma, Inc. announced that detailed results from the Phase 2 BrigHtn trial evaluating the safety and efficacy of baxdrostat in treatment-resistant hypertension were published online today in the New England Journal of Medicine. Baxdrostat is a highly selective, once da..."
11/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer WALTHAM, MA, November 7, 2022 -- CinCor Pharma, Inc. announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer , effective November 4. An accomplished financial executive with product launch and commercialization experience in cardiovascular therapeutics, Mr. Kalb brings over 25 years of global financial, operations and strategic transactional experience. He is replacing Terry Coelho who is retiring from her role as Executive Vice President, CFO and Chief Business Development Officer. “We are delighted to welcome Mike to the CinCor team during this important time as we approach potential commercialization of baxdrostat,” said Marc de Garidel,..."
11/04/2022 8-K/A Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/26/2022 SC 13G/A venBio Global Strategic Fund III, L.P. reports a 4.9% stake in CinCor Pharma, Inc.
08/19/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/12/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy